# Test Report: Personas 3 & 4

## User 3: Dr. Priya Patel — Medicinal Chemist
**Profile**: Senior Scientist at a biotech company, expert in structure-based drug design, SAR analysis, ADMET profiling. Expects chemical structure rendering, activity data, selectivity panels.

---

### UC-03: Search for Vemurafenib and view molecular properties, activity data, SMILES

**Outcome**: PARTIAL  
**Estimated Time**: 3 minutes  
**Severity**: P1-critical, P2-major, P3-minor

**Test Walkthrough**:
Dr. Patel navigates to `/search` and types "Vemurafenib". The search returns a result from the API at `/api/search`.

**What works**:
- Search finds Vemurafenib (CHEMBL1089) in the mock database
- Shows: chemblId, name, moleculeType ("Small molecule"), SMILES, MW (489.92), LogP (3.6), maxPhase (Approved)
- SMILES string is displayed (truncated with ellipsis, full on hover)

**What's missing/broken**:
- **P1**: The `/api/search` route (route.ts:36) uses a LOCAL MOCK DATABASE of 12 compounds, NOT the real ChEMBL API. The comment on line 36 says `// TODO: Replace with actual ChEMBL API integration`. This means any compound not in the hardcoded list returns zero results.
- **P1**: No activity data whatsoever — no IC50, EC50, Ki values, no bioassay results, no dose-response data. A medicinal chemist needs this as the primary data point.
- **P1**: No chemical structure rendering — SMILES is displayed as text only. No 2D depiction (RDKit, JSME, Ketcher), no 3D viewer. For a med-chem platform this is a dealbreaker.
- **P2**: No selectivity data — cannot compare activity across related targets (e.g., BRAF V600E vs wild-type BRAF vs CRAF)
- **P2**: No links to external databases (ChEMBL, PubChem, DrugBank) for the compound
- **P3**: No HBA, HBD, PSA, rotatable bonds, or other Rule-of-5 descriptors shown despite the Prisma schema defining them (hba, hbd, psa, qed fields on Compound model)
- **P3**: No export functionality (CSV, SDF)

**User Reflection**: *"This is essentially a Google search with worse results. I can't see the structure, there's no activity data, and the database seems to have barely a dozen compounds. I'd go straight to ChEMBL directly — at least there I'd get bioactivity tables and structure images."*

**Problems Identified**:
1. P1 — Mock database instead of real ChEMBL API integration
2. P1 — No chemical structure visualization/rendering
3. P1 — No bioactivity data (IC50/EC50/Ki values)
4. P2 — No selectivity panels or SAR data
5. P2 — No external database cross-links
6. P3 — Missing drug-likeness descriptors (HBA, HBD, PSA, TPSA, rotatable bonds)
7. P3 — No data export (CSV, SDF, MOL)

---

### UC-06: Look up a drug's mechanism of action and supporting evidence chain

**Outcome**: PARTIAL  
**Estimated Time**: 5 minutes  
**Severity**: P1-critical, P2-major

**Test Walkthrough**:
Dr. Patel navigates to `/disease-biology/mechanisms`. The page shows 4 hardcoded MoA studies and 3 evidence streams.

**What works**:
- Shows 4 MoA studies with pathway, method, status, confidence %, and evidence text
- Studies cover relevant pathways: MAPK/ERK, Wnt/GSK3, JAK-STAT, PI3K/AKT/mTOR
- Confidence bars give visual indication of validation strength
- Status badges (Validated/Under review/Investigating) are clear
- Evidence streams section (Terrain2Drug, Market2Drug, Paper2Drug) shows analysis counts

**What's missing/broken**:
- **P1**: ALL DATA IS HARDCODED in the component (mechanisms/page.tsx lines 24-67). Not connected to any database or API. Will never update.
- **P1**: No evidence chain — the "evidence" field is a single sentence string, not a linked chain of literature references, experimental data, and pathway connections. Dr. Patel expects to click through from MoA → pathway diagram → experimental evidence → PubMed references.
- **P1**: No pathway visualization — no interactive pathway diagrams (KEGG-style, Reactome-style). Just text labels like "MAPK/ERK".
- **P2**: Evidence streams (Terrain2Drug, Market2Drug, Paper2Drug) are just cards with counts — clicking them does nothing, no drill-down.
- **P2**: No compound-to-MoA linkage — cannot go from a specific compound to see its mechanism
- **P2**: No confidence score methodology — no explanation of how the 65-92% confidence values are derived
- **P3**: The "selectedStudy" state in the component tracks which card is selected (ring-2 ring-primary) but selecting a card does absolutely nothing — no detail panel, no expanded view

**User Reflection**: *"I see that BRAF V600E → MEK → ERK is 'Validated' at 92% confidence, but what does that actually mean? Where's the supporting data? I can't see any pharmacological evidence, binding assays, or selectivity data. The evidence field is a single sentence — I need linked PubMed IDs, crystal structures, and functional assay results."*

**Problems Identified**:
1. P1 — All data hardcoded, not from database/API
2. P1 — No evidence chain with linked references
3. P1 — No pathway visualization
4. P2 — Evidence streams are non-interactive placeholder cards
5. P2 — No compound-to-MoA linkage
6. P3 — Card selection state does nothing

---

### UC-13: Evaluate target druggability — tractability, binding sites, known ligands

**Outcome**: FAILURE  
**Estimated Time**: 8 minutes of searching, then give up  
**Severity**: P1-critical

**Test Walkthrough**:
Dr. Patel looks for target druggability assessment. She checks:
1. `/targets` — Shows 6 hardcoded targets with gene name, organism, disease area, compound count, and target class. No druggability information at all.
2. `/disease-biology/target-board` — Has target prioritization but no druggability metrics.
3. `/pharmacology/optimization` — Shows optimization campaigns and ADMET dashboard, but this is compound-level, not target-level druggability.
4. `/compounds` — Shows 10 hardcoded compounds with basic properties. No target-level analysis.

**What works**:
- The `/targets` page exists and lists 6 targets
- Target class labels (Kinase, Enzyme, Protease) provide minimal druggability signal

**What's missing/broken**:
- **P1**: No druggability assessment page or feature exists anywhere in the platform
- **P1**: No tractability scores (small molecule, antibody, other modalities)
- **P1**: No structural data — no PDB links, no binding site information, no protein structure viewer
- **P1**: No known ligand library per target — the "compoundCount" field on target cards shows a number but it's hardcoded and clicking leads nowhere
- **P1**: No pharmacophore models, no binding pocket analysis
- **P2**: Target cards have no click-through to detail pages — they are static display-only cards
- **P2**: No link to Open Targets tractability data or ChEMBL target profiles
- **P2**: No UniProt ID shown on target cards (despite the Prisma schema having a uniprotId field on the Target model)

**User Reflection**: *"This platform claims to support drug discovery but has zero target druggability data. I can't assess whether a target is tractable for small molecules, there are no binding site views, no crystal structures, no known ligands. This is the most basic requirement for a medicinal chemist starting any drug design project. I would not use this platform."*

**Problems Identified**:
1. P1 — No druggability assessment feature exists
2. P1 — No structural data or PDB links
3. P1 — No binding site information
4. P1 — No known ligand library per target
5. P2 — Target cards are non-interactive
6. P2 — Missing UniProt ID display
7. P2 — No Open Targets/ChEMBL integration for target profiles

---

### UC-16: Assess resistance mechanisms for EGFR inhibitors with literature evidence

**Outcome**: PARTIAL (very limited)  
**Estimated Time**: 10 minutes  
**Severity**: P1-critical

**Test Walkthrough**:
Dr. Patel searches for EGFR resistance information across the platform:

1. `/disease-biology/mechanisms` — Has one study "EGFR → PI3K → AKT Resistance" (MOA-004) with status "Investigating", confidence 65%, evidence: "Resistance mechanism identified through multi-agent LLM analysis". This is the only reference to EGFR resistance on the entire platform.
2. `/pharmacology/optimization` — Campaign OPT-004 "EGFR 4th-Gen Resistance" mentions C797S activity as an objective with 18 compounds tested. Best candidate SDD-0139 at 22nM with hERG flag.
3. `/drug` page — Shows "Osimertinib-R" (SDD-0078) repositioned from NSCLC (T790M) to NSCLC (C797S), currently Phase 1.
4. `/disease` page — Subtype DS-006 "EGFR-mutant NSCLC" lists biomarkers [EGFR L858R, EGFR T790M, EGFR C797S].
5. `/clinical/biomarkers` page — Has "ctDNA EGFR T790M" biomarker entry with 88% sensitivity.

**What works**:
- There IS scattered information about EGFR resistance across multiple pages
- The EGFR C797S mutation is mentioned as a key biomarker
- An optimization campaign specifically targets C797S resistance

**What's missing/broken**:
- **P1**: No dedicated resistance mechanism page or consolidated view. Information is scattered across 5 different pages with no cross-linking.
- **P1**: No resistance mutation catalog — should list T790M, C797S, L858R with frequency data, mechanism, and rescue strategies. Instead, mutations are mentioned in passing as biomarker names.
- **P1**: No literature evidence linked — the MoA study says "identified through multi-agent LLM analysis" but provides zero PubMed references, no clinical data, no structural basis.
- **P1**: No structural visualization of mutations — cannot see where C797S is on the EGFR kinase domain, how it affects drug binding
- **P2**: No rescue strategy comparison — which next-gen inhibitors overcome C797S? The platform mentions Osimertinib-R but doesn't compare it to other approaches
- **P2**: Data is fragmented — a user has to visit 5 pages to piece together the EGFR resistance story, with no navigation linking them
- **P2**: All data is hardcoded and static

**User Reflection**: *"I found bits and pieces about EGFR resistance scattered across the platform, but nothing I can work with systematically. There's no mutation frequency data, no structural basis for resistance, no comparison of rescue strategies. For a critical topic in oncology drug development, this is woefully inadequate. I'd use cBioPortal or COSMIC instead."*

**Problems Identified**:
1. P1 — No consolidated resistance mechanism view
2. P1 — No mutation catalog with frequency/mechanism/rescue data
3. P1 — No literature evidence links
4. P1 — No structural visualization of mutations
5. P2 — No rescue strategy comparison
6. P2 — Information fragmented across 5 pages with no cross-linking
7. P2 — All data hardcoded

---

### UC-18: Evaluate target x modality x residue-specific approach (EGFR C797S + covalent inhibitor + specific binding mode)

**Outcome**: FAILURE  
**Estimated Time**: 15 minutes of searching, then give up  
**Severity**: P1-critical

**Test Walkthrough**:
Dr. Patel tries to find residue-level analysis for EGFR C797S with a covalent inhibitor approach:

1. `/targets` — EGFR card shows gene, organism, disease area, 42 compounds, Kinase class. No residue-level data.
2. `/compounds` — Lists Osimertinib (EGFR T790M target), Erlotinib, Gefitinib (EGFR target). No binding mode or covalent mechanism info.
3. `/drug` — Osimertinib-R targeting EGFR T790M → C797S repositioning. "Covalent EGFR inhibitor" in MoA field but no binding mode details.
4. `/pharmacology/optimization` — OPT-004 mentions C797S activity as objective but no structural data.
5. `/disease-biology/mechanisms` — MOA-004 mentions PI3K/AKT resistance pathway but not covalent binding.

**What works**:
- The C797S target is recognized in drug repositioning data
- Osimertinib is correctly identified as a covalent EGFR inhibitor

**What's missing/broken**:
- **P1**: No residue-level analysis capability exists — this is a core user requirement mentioned in the use case definition. The platform has no concept of individual residues, binding sites, or structural pharmacology.
- **P1**: No structural context — no protein structure viewer, no PDB links, no binding pocket visualization
- **P1**: No covalent inhibitor analysis — cannot assess warhead chemistry, cysteine reactivity, reversibility
- **P1**: No selectivity implications — how does C797S mutation affect selectivity for different inhibitor scaffolds?
- **P1**: No binding mode analysis — no docking results, no molecular dynamics, no FEP data
- **P1**: Cannot cross-reference target x modality x residue — there is no data model that supports this three-way intersection
- **P2**: No modality-specific design tools — covalent inhibitors have unique design considerations not addressed anywhere

**User Reflection**: *"This use case represents exactly what a modern drug discovery platform should support — the intersection of target biology, chemical modality, and structural pharmacology. This platform can't do any of it. There's no structural data, no residue-level analysis, no covalent chemistry tools. This is a fundamental gap that would require building the platform from scratch for this use case."*

**Problems Identified**:
1. P1 — No residue-level analysis exists
2. P1 — No protein structure viewer or PDB integration
3. P1 — No covalent inhibitor analysis tools
4. P1 — No binding mode analysis
5. P1 — No target x modality x residue data model
6. P2 — No modality-specific design considerations

---

## User 4: Dr. James Wright — Clinical Pharmacologist
**Profile**: Translational medicine director, expert in PK/PD modeling, clinical trial design, regulatory knowledge. Expects trial data integration, patient stratification, regulatory pathway guidance.

---

### UC-04: Browse disease subtypes (BRAF V600E Melanoma) and view biomarkers, standard of care, unmet need

**Outcome**: PARTIAL  
**Estimated Time**: 3 minutes  
**Severity**: P2-major

**Test Walkthrough**:
Dr. Wright navigates to `/disease` and clicks the "Subtypes" tab, then filters by "Melanoma".

**What works**:
- Disease subtypes tab shows 8 subtypes across 5 disease groups
- BRAF V600E Melanoma (DS-001) is present with:
  - Prevalence: ~50% of melanomas
  - Biomarkers: BRAF V600E, MEK, PD-L1 (shown as colored pills)
  - Standard of care: BRAF/MEK inhibitors
  - Unmet need: High (red badge)
- Filter by group (Melanoma) works — shows DS-001 (BRAF V600E) and DS-002 (NRAS Mutant)
- NRAS Mutant Melanoma also shown with its own biomarkers and standard of care
- Unmet need badges color-coded (red=high, yellow=medium, green=low)

**What's missing/broken**:
- **P1**: ALL DATA IS HARDCODED (disease/page.tsx lines 86-159). Not connected to database or external source. Will never update.
- **P2**: No provenance/references — where does "~50% of melanomas" come from? No PubMed links, no data source citation
- **P2**: Subtypes have no click-through to detail pages — cards are display-only
- **P2**: No cross-reference to targets page — biomarker "BRAF V600E" is just text, not a link to the BRAF target card
- **P2**: No treatment algorithm or decision tree — standard of care is a single text line without treatment sequencing
- **P2**: No epidemiology data — incidence, mortality, survival rates missing
- **P3**: No mechanism for adding new subtypes or updating data
- **P3**: ICD code shown only on Disease Groups tab, not on Subtypes

**User Reflection**: *"The subtype cards give me the basics — I can see that BRAF V600E Melanoma has high unmet need and identify the relevant biomarkers. But there's no depth. Where are the references? What's the treatment sequence? I need to know first-line through third-line therapy, resistance patterns, and emerging options. This is a good wireframe but not a working clinical tool."*

**Problems Identified**:
1. P1 — All data hardcoded
2. P2 — No provenance or literature references
3. P2 — No click-through to detail pages
4. P2 — No cross-referencing between subtypes and targets
5. P2 — No treatment algorithms
6. P2 — No epidemiology data
7. P3 — No data update mechanism

---

### UC-05: View patient cohort data for a disease — size, data types, recruitment status

**Outcome**: PARTIAL  
**Estimated Time**: 2 minutes  
**Severity**: P2-major

**Test Walkthrough**:
Dr. Wright navigates to `/disease` and clicks the "Cohorts" tab.

**What works**:
- Cohorts table shows 5 cohorts with:
  - Name (e.g., BRAF-MEL-2024)
  - Disease association
  - Size (450 to 1,200 patients)
  - Source institution (UAB Cancer Center, ADNI, MD Anderson, etc.)
  - Data types (shown as colored pills: Genomics, Imaging, Clinical outcomes, etc.)
  - Status (recruiting/active/completed with colored badges)
- Table is well-structured with good visual hierarchy

**What's missing/broken**:
- **P1**: ALL DATA IS HARDCODED (disease/page.tsx lines 161-207). Cohort sizes, recruitment status will never update.
- **P2**: No enrollment timelines — when did recruitment start? What's the enrollment rate?
- **P2**: No click-through to cohort detail pages — cannot see demographics, inclusion/exclusion criteria, consent status
- **P2**: No link to clinical trials — cohort BRAF-MEL-2024 should link to trial BRAF-301
- **P2**: No patient-level data summary — age distribution, sex ratio, racial/ethnic composition
- **P2**: Status values are static — a "recruiting" cohort will always show "recruiting"
- **P3**: No data sharing/access request mechanism
- **P3**: No sorting or filtering on the cohort table

**User Reflection**: *"I can see there's a 450-patient melanoma cohort at UAB with genomics and imaging data — that's useful context. But the recruitment status is clearly static, there's no enrollment curve, no demographics, and I can't drill down into the data types. As a clinical pharmacologist planning a translational study, I need to know the patient population characteristics before designing a trial around this cohort."*

**Problems Identified**:
1. P1 — All data hardcoded, never updates
2. P2 — No enrollment timelines or rates
3. P2 — No cohort detail pages
4. P2 — No linkage to clinical trials
5. P2 — No patient demographics summary
6. P3 — No data access/sharing mechanism
7. P3 — No table sorting/filtering

---

### UC-10: Assess clinical trial landscape for a target (EGFR) — active trials, phases, sponsors, endpoints

**Outcome**: FAILURE  
**Estimated Time**: 10 minutes  
**Severity**: P1-critical

**Test Walkthrough**:
Dr. Wright looks for EGFR clinical trial landscape:

1. `/clinical/trials` — Shows "Trial Simulations" page with 4 hardcoded trials (BRAF-301, TAU-201, JAK-301, SYNTH-101). NONE are EGFR trials. These are internal simulated trials, not real ClinicalTrials.gov data.
2. `/search` — Can search for "EGFR" but this searches compounds, not trials.
3. `/targets` — EGFR card shows 42 compounds but no trial links.
4. `/disease` — EGFR-mutant NSCLC subtype mentions biomarkers but no trials.
5. `/clinical/biomarkers` — Has ctDNA EGFR T790M biomarker but no trial cross-reference.
6. `/pharmacology/optimization` — OPT-004 "EGFR 4th-Gen Resistance" campaign, but this is internal optimization not external trial landscape.

**What works**:
- The `/clinical/trials` page exists and shows well-designed trial simulation cards
- Trial cards include: design, arms, sample size, primary endpoint, simulated outcome, statistical power, duration
- The concept of virtual trials / digital twins (SYNTH-101) is innovative

**What's missing/broken**:
- **P1**: No ClinicalTrials.gov integration — this is THE essential feature for clinical trial landscape analysis
- **P1**: The trials page only shows internal simulated/planned trials (4 hardcoded), not the real-world landscape of EGFR trials (thousands exist on ClinicalTrials.gov)
- **P1**: No trial search capability — cannot search by target, indication, phase, sponsor
- **P1**: No competitive landscape view — who else is running EGFR trials? What are the endpoints?
- **P2**: Internal trials page has no link to ClinicalTrials.gov NCT numbers
- **P2**: No trial comparison feature — cannot compare endpoints, enrollment criteria across trials
- **P2**: All 4 shown trials are hardcoded (trials/page.tsx lines 21-71)
- **P3**: Trial simulation cards don't link to their corresponding compounds or targets

**User Reflection**: *"I came to assess the EGFR trial landscape and found four internal trial simulations — none of which are EGFR-related. Where's the connection to ClinicalTrials.gov? I need to see the 500+ active EGFR trials, filter by phase, sponsor, and endpoint, and identify competitive positioning. This platform has no external trial data integration whatsoever. I'd use ClinicalTrials.gov or Citeline directly."*

**Problems Identified**:
1. P1 — No ClinicalTrials.gov integration
2. P1 — Only shows 4 internal simulated trials, not real trial landscape
3. P1 — No trial search by target/indication/phase/sponsor
4. P1 — No competitive landscape view
5. P2 — No NCT number links
6. P2 — No trial comparison feature
7. P3 — No cross-linking to compounds/targets

---

### UC-11: Review regulatory status of a drug candidate — FDA/EMA submissions, approvals, labels

**Outcome**: FAILURE  
**Estimated Time**: 10 minutes  
**Severity**: P1-critical

**Test Walkthrough**:
Dr. Wright searches for FDA/EMA regulatory status across the platform:

1. `/regulatory/licensing` — Shows "Copyright / OSDD2 License" page about data asset licensing (CC BY-SA, Apache 2.0, OSDD2), FAIR compliance scores, and open science governance. This is about **data licensing**, not drug regulatory status.
2. `/regulatory/clinical-docs` — Shows clinical trial documents (protocols, consent forms, investigator brochures, safety reports, submissions). Has an "IND Application — BRAF Program" entry. This is internal document management, not FDA/EMA regulatory status tracking.
3. `/regulatory/irb` — Shows IRB protocol submissions and approvals. This is about institutional review board compliance, not drug regulatory submissions.
4. `/regulatory/decisions` — Shows Go/No-Go decision reports for IP filings, partnerships, compliance milestones. Closest to what's needed but covers business decisions, not FDA/EMA regulatory pathway.
5. `/regulatory/business` — Likely contains business/commercial regulatory info (not checked in detail).
6. `/drug` — Drug page shows development stage (discovery → approved) but no FDA/EMA submission info. Thalidomide is marked "Approved" but there's no regulatory timeline or approval details.

**What works**:
- Regulatory section exists with 5 sub-pages covering different aspects
- Clinical docs page has IND Application tracking
- Decision reports show Go/No-Go milestones with confidence scores
- IRB protocol tracking is well-structured

**What's missing/broken**:
- **P1**: No FDA/EMA regulatory status tracking for drug candidates — the regulatory section covers data licensing, IRB protocols, and business decisions, but NOT drug approval status
- **P1**: No regulatory timeline — when was IND filed? When does FDA review conclude? What are the PDUFA dates?
- **P1**: No regulatory pathway guidance — 505(b)(1) vs 505(b)(2) vs BLA? Accelerated approval? Breakthrough therapy?
- **P1**: No label information — drug labels, prescribing information, black box warnings
- **P2**: No FDA/EMA cross-reference — Drugs@FDA, EMA EPAR integration
- **P2**: No regulatory milestone tracking (pre-IND meeting, IND filing, Phase end meetings, NDA/BLA, PDUFA)
- **P2**: The IND Application entry in clinical-docs is a document management entry, not a regulatory submission tracker
- **P2**: Drug page "stage" field (discovery/preclinical/phase-1/.../approved) is too coarse for regulatory planning
- **P3**: All regulatory data is hardcoded

**User Reflection**: *"I expected to find a regulatory status dashboard showing where each drug candidate stands in the FDA/EMA pathway — IND status, phase results submission, NDA filing timeline. Instead, the regulatory section is about data licensing and IRB approvals, which are important but completely different. For regulatory planning, I'd need to use RegulatoryFocus, FDA.gov, or our internal RA tracking system."*

**Problems Identified**:
1. P1 — No FDA/EMA drug regulatory status tracking
2. P1 — No regulatory timeline/milestone tracker
3. P1 — No regulatory pathway guidance (505(b)(1), accelerated approval, etc.)
4. P1 — No drug label/prescribing information
5. P2 — No FDA/EMA database integration (Drugs@FDA, EPAR)
6. P2 — No regulatory milestone tracking
7. P3 — All data hardcoded

---

## Summary Statistics

### Dr. Priya Patel (Medicinal Chemist)
| Use Case | Outcome | Severity | Key Issue |
|----------|---------|----------|-----------|
| UC-03 | Partial | P1 | Mock API, no structure rendering, no activity data |
| UC-06 | Partial | P1 | Hardcoded data, no evidence chains, no pathway viz |
| UC-13 | Failure | P1 | No druggability feature exists |
| UC-16 | Partial | P1 | Resistance info scattered, no catalog, no references |
| UC-18 | Failure | P1 | No residue-level analysis, no structural pharmacology |

**Overall Assessment**: 0/5 successful, 3/5 partial, 2/5 failure. The platform lacks the fundamental data infrastructure a medicinal chemist needs: structure rendering, activity data, druggability assessment, and structural pharmacology.

### Dr. James Wright (Clinical Pharmacologist)
| Use Case | Outcome | Severity | Key Issue |
|----------|---------|----------|-----------|
| UC-04 | Partial | P2 | Hardcoded data, no provenance, no drill-down |
| UC-05 | Partial | P2 | Hardcoded cohorts, no live enrollment data |
| UC-10 | Failure | P1 | No ClinicalTrials.gov integration, only internal sims |
| UC-11 | Failure | P1 | No FDA/EMA regulatory tracking |

**Overall Assessment**: 0/4 successful, 2/4 partial, 2/4 failure. The platform has reasonable UI mockups for disease data and cohorts but completely lacks external data integration for clinical trial landscape and regulatory status — the two most critical features for a clinical pharmacologist.

### Unique Issues Found (Deduplicated)
Total: 48 individual problems identified

**P1-Critical**: 25
- Mock/hardcoded data instead of live databases (affects all pages)
- No chemical structure rendering
- No bioactivity data (IC50/EC50/Ki)
- No druggability assessment
- No protein structure viewer/PDB integration
- No residue-level analysis
- No ClinicalTrials.gov integration
- No FDA/EMA regulatory tracking
- No evidence chains with literature references
- No pathway visualization

**P2-Major**: 17
- No cross-referencing between entities (targets ↔ compounds ↔ trials ↔ diseases)
- No detail pages (all entities are display-only cards/rows)
- No external database links
- No data provenance/citations
- No treatment algorithms
- No competitive landscape
- No export functionality

**P3-Minor**: 6
- Missing descriptors already in schema
- No sorting/filtering on some tables
- Non-functional interactive states (selected cards do nothing)
